Back to News
Market Impact: 0.25
Lundbeck Reports Positive Phase IV THRIVE Results For Eptinezumab In Migraine
Source: Nasdaq
Healthcare & BiotechProduct Launches
H. Lundbeck announced headline results from the Phase IV THRIVE trial of intravenous eptinezumab in adults with migraine who had an inadequate response to one prior CGRP-targeting treatment. The provided article text does not include efficacy, safety, or financial results, limiting assessment of the trial's clinical and commercial significance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
HLUN.B0.35
More News
- One of our most recent defensive buys cleared a hurdle and its stock jumped
- Cullinan initiates FDA filing for lung cancer drug zipalertinib
- Moderna to replace Warner Bros Discovery on Nasdaq 100
- Why McKesson Stock Soared More Than 5% Higher Today
- This biotech making precision medicines for cancer could nearly triple, says JPMorgan
- The Dow's rough month, Micron's revenue surge, Google launches Gemini 4 and more in Morning Squawk
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AlphaSense vs Hebbia vs AllMind: Choose by Workflow
- AllMind Discusses Ontario's AI Economy with Minister Stephen Crawford and Supply Ontario CEO James Wallace